![Henrik Olsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henrik Olsen
Corporate Officer/Principal bei Gliknik, Inc.
Profil
Henrik S.
Olsen is currently working as Vice President-Drug Discovery at Gliknik, Inc. He previously worked as a Scientist at Human Genome Sciences, Inc. He completed his undergraduate degree from the University of Aarhus.
Aktive Positionen von Henrik Olsen
Unternehmen | Position | Beginn |
---|---|---|
Gliknik, Inc.
![]() Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Henrik Olsen
Unternehmen | Position | Ende |
---|---|---|
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Henrik Olsen
University of Aarhus | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Gliknik, Inc.
![]() Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |